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Introduction
Uveitis in JIA can be severe and immunosoppressive
therapies may not be sufficient. Anti-TNF-alfa agents
(Infliximab, Adalimumab) have been proposed. The per-
centage of success is different among series and no con-
trolled trials have been published yet. Abatacept, a
selective T-cell co-stimulation modulator, has been
shown to be a valid alternative to anti-TNF-alfa agents
in patients with refractory uveitis (Angels-Han S.2008;
Zulian 2010).
Case report
We report on a 20-years-old girl, affected since one year
of age, by a severe form of poliarticular JIA. She
received immunosuppressors (Metrotrexate, Azathiopr-
ine…) associated with steroids, with no articular benefit.
When Enbrel plus Metrotrexate was started, she got
into remission. After one year she presented uveitis
bilaterally, so steroids were started again. She obtained
partial ocular improvement, receiving Infliximab plus
Metrotrexate, but the former was suspended because of
an adverse reaction (dyspnea, rash) and Adalimumab
was started, with no side effects. After three years, she
had flare for uveitis and arthritis. Adalimumab was sus-
pended and Abatacept was started, with no side effects.
After 12 months, uveitis seems to be stable, while arthri-
tis, after a good initial response, seems to be active
again.
Conclusions
In our case, Abatacept was a valid drug in uveitis treat-
ment, less effective in arthritis. In the literature, there
are other reports of good response of ocular inflamma-
tion, with reduced effectiveness on articular flares
(Kenawy N., 2011). Long- term follow-up in patients
with severe uveitis and JIA treated with Abatacept is
necessary to check if this drug is a valid alternative to
anti- TNF drugs.
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